A Rare Case of Hemoglobin E/Beta-Thalassemia and Systemic Lupus Erythematosus

Ibrahim Khamees 1, Ibrahim Mohammad Obeidat 1, Waail Rozi 1, Mohamed A. Yassin 2

1. Internal Medicine, Hamad Medical Corporation, Doha, Qatar 2. Hematology and Oncology, Hamad General Hospital, Doha, Qatar

Corresponding author: Ibrahim Khamees, ibrahim_khamees@hotmail.com

Abstract

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease, with multisystemic involvement. Hemoglobin E/beta-thalassemia (HbE/beta-thalassemia) is the genotype responsible for approximately one-half of all severe beta-thalassemia worldwide. When beta-thalassemia and SLE coexist, SLE seems to have a more severe course. Here we report a 32-year-old female who presented with dizziness and fatigue was found to have severe hemolytic anemia with thrombocytopenia. Upon further evaluation, she was diagnosed with HbE/beta-thalassemia and SLE, which is a very rare association. In SLE patients, anemia usually results from the disease itself, but it is important to think of other coexisting conditions like thalassemia.

Categories: Internal Medicine, Rheumatology, Hematology

Keywords: systemic lupus erythematosus, hemolytic anemia, hemoglobin e/beta-thalassemia

Introduction

Systemic lupus erythematosus (SLE) is a multisystem chronic inflammatory disease of autoimmune etiology, with the hematologic system being affected in most cases. SLE can cause anemia in multiple ways, one of them is hemolytic anemia. It can also cause thrombocytopenia especially if associated with antiphospholipid antibody syndrome involving autoantibodies against platelets, glycoprotein Ilb/IIia or thrombopoietin receptor [1]. With that being mentioned, some patients with SLE can have another condition that can cause anemia as well. It was found that the prevalence of beta-thalassemia in patients with SLE is lower than that in general population, but if coexistence happens, SLE seems to have a more severe course [2].

Hemoglobinopathies are considered the commonest recessive monogenic disorders in the world, and they constitute a major burden on the financial and health care systems globally. Beta-thalassemia presents with either decreased (β+) or absence (β 0) of the beta-globin chains in the HbA protein, which leads to buildup of extra unbound alpha-globin chains in the erythroid precursors in the bone marrow and in the red blood cells (RBCs), resulting in ineffective erythropoiesis and hemolysis. Around 1.5% of the world population are heterozygotes (carriers) of the beta-thalassemias; there is a high incidence in the Middle East, the Indian subcontinent, Southeast Asia, and Melanesia to the Pacific Islands [3].

Chronic blood transfusion (CBT) is essential in the management of individuals with beta-thalassemia major. However, it has major complications including iron overload that necessitates regular monitoring and treatment by long-term iron chelation therapy to protect
the patients from endocrinopathies and cardiomyopathies, which can be fatal [4-7]. Skeletal changes may result from the expansion of the bone marrow, and development of masses from extramedullary hematopoiesis. In spite of that, CBT causes iron overload that requires monitoring and management through long-term iron chelation therapy [8].

Case Presentation

A 32-year-old female patient presented with a history of dizziness and fatigue increasing in the last few weeks. She came to the country around seven months back and mentioned having multiple blood transfusions in her home country for anemia. On examination, the patient had severe pallor, jaundice and hepatosplenomegaly.

Initial laboratory investigations are given in Table 1

| Investigation               | Result          | Normal range       |
|-----------------------------|-----------------|--------------------|
| White blood cell count      | 4.5 x 10^3/μL   | 4-10 x 10^3/μL     |
| Red blood cell count        | 1.7 x 10^6/μL   | 3.8-4.8 x 10^6/μL  |
| Hemoglobin                  | 3.1 gm/dL       | 12-15 gm/dL        |
| Hematocrit                  | 11.4%           | 36%-46%            |
| Mean corpuscular volume     | 65.9 fl         | 83-101 fl          |
| Platelet count              | 72 x 10^9/μL    | 50-400 x 10^9/μL   |
| Reticulocyte %              | 4.2%            | 0.5%-2.5%          |
| Reticulocyte index          | 0.46%           | >2.5%              |
| Lactate dehydrogenase       | 933 U/L         | 135-214 U/L        |
| Haptoglobin                 | >10 mg/dL       | 30-200 mg/dL       |
| Total bilirubin             | 57 μmol/L       | 0-21 μmol/L        |
| Direct bilirubin            | 12 μmol/L       | 0-5 μmol/L         |
| Ferritin                    | 2,519 μg/L      | 12-160 μg/L        |
| Iron                        | 43 μmol/L       | 6-35 μmol/L        |
| Fe saturation               | 90%             | 15%-45%            |
| Direct antiglobulin test    | +2 for immunoglobulin G |                |
| Elution test                | Negative        |                    |

TABLE 1: Initial laboratory investigations

Peripheral smear (Figure 1) showed moderate hypochromic microcytic anemia with scattered
polychromatic cells, many nucleated RBCs and significant anisopoikilocytosis, including many scattered tear drops, ovalocytes, schistocytes, irregularly contracted cells and some microspherocytes.

Kidney function, international normalized ratio and fibrinogen were all normal. Ultrasound of the abdomen was done, which was positive for hepatosplenomegaly. The patient was resuscitated with packed RBC transfusion and admitted. With the history of multiple blood transfusions in the past, the iron overload (probably due to multiple blood transfusions) and the low mean corpuscular volume (MCV), hemoglobin electrophoresis was sent and it showed the findings in Table 2, based on that the patient was diagnosed with HbE/beta-thalassemia.

| Hemoglobin type | Percentage |
|----------------|------------|
| Hb A           | 00         |
| Hb A2          | 2.0        |
| Hb F           | 25         |
| Hb S           | 00         |
| Hb E           | 73         |

**TABLE 2: Hemoglobin electrophoresis**
Autoimmune workup revealed positive antinuclear antibody (ANA), anti-double-stranded DNA (anti-ds-DNA) and low complement protein 3 (C3), so the patient was diagnosed with SLE and started on hydroxychloroquine. The patient was hospitalized for five days, during which Hb picked up to 9.9 gm/dL and platelets count decreased to 38 x 10^3/μL, and was discharged with a plan to follow complete blood cell (CBC) in the clinic after two weeks. However, upon repeating CBC after two weeks, the patient had anemia with Hb of 6.9 mg/dL, white blood cell (WBC) of 3.7 x 10^5/μL, absolute neutrophilic count of 2.2 x 10^3/μL and platelet count of 12 x 10^3/μL, so she was admitted again. She complained of easy fatigability and exertional shortness of breath, but no apparent bleeding from any site. On examination, she had pallor, hepatosplenomegaly but no skin rash.

Her lab investigations that time also revealed hemolytic anemia with low reticulocyte index 0.55 and severe thrombocytopenia 12 x 10^3/μL, increased (anti-ds-DNA) titer, low C3 and normal kidney function test. She was managed as a case of SLE flare causing thrombocytopenia and anemia complicated by thalassemia, for which she was started on oral prednisolone 1 mg/kg which was changed to intravenous methylprednisolone 10 mg/kg, along with platelets, fresh-frozen plasma and packed RBC transfusions. She was also started on deferasirox (Jadenu) 720 mg daily due to iron overload. In the next few days, the platelet count improved to 47 x 10^3/μL and her Hb stabilized around 9 mg/dL, so she was discharged on oral prednisolone with a follow-up after one week to follow CBC. In the follow-up, her platelet count was 119 x 10^3/μL and her Hb was 9.3 mg/dL, so prednisolone was tapered with close follow-up in rheumatology and hematology clinics.

**Discussion**

We described a patient who has HbE/beta-thalassemia double heterozygosity, admitted with severe anemia and thrombocytopenia, found to have SLE. The association between beta-thalassemia in general and SLE is rare, and it is rarer in HbE/beta-thalassemia based on the reported case all over the world. However, near the beta-globin locus at 11p15.5, there are specific immunity genes, which match with the autoimmunity susceptibility [9].

Hematologic abnormalities are common in SLE, and all three blood cell lines can be affected. Anemia of chronic disease is the most common type of anemia in SLE patients, autoimmune hemolytic anemia is relatively rare and severe thrombocytopenia is rare as well [10].

In general, HbE/beta-thalassemia is a thalassemia syndrome of intermediate severity with a diverse clinical spectrum. Compared to a normal individual, HbA is replaced by HbE and HbF in patients with HbE/beta-thalassemia. HbE constitutes between 30% and 70% of the hemoglobin with the rest HbF. In some cases of HbE thalassemia as HbE beta+ thalassemia, different mutations lead to variable amounts of HbA, which causes variable levels of disease severity [11].

In one study that included 177 patients with SLE, there were 17 patients with beta-thalassemia. This study concluded that the prevalence of beta-thalassemia in patients with SLE seems to be lower than that in the general population. However, when the two conditions coexist, SLE seems to have a more severe course. The incidence of complications was more severe in SLE with beta-thalassemia. However, the reason behind that was not clear. It could be related to low complement 3 and complement 4, and/or due to presence of anti-SSA autoantibodies (anti-Sjögren’s syndrome-related antigen A autoantibodies, also called anti-Ro antibodies). Also, higher occurrence of atherosclerotic events and loss of the ability to bind immune complexes have been described in beta-thalassemia which could be related to a more severe disease [2].
In one literature review, the authors highlighted the diagnostic difficulty of SLE in patients with other type of hemolytic anemia which is sickle cell disease (SCD). They attributed that to the similar manifestations of both diseases, including anemia and skeletal pain. They concluded that certain features might alert the physicians to the possibility of both diseases coexistence like joint pain resistant to usual analgesic measures, presence of proteinuria or presence of leukopenia and thrombocytopenia in SCD patients [12].

Many cases reported association of beta-thalassemia trait and SLE, but upon reviewing the literature we found only one case about HbE/beta-thalassemia and SLE disease [13]. In our case, we faced more severe presentation in the hematological system. Meanwhile for the patient who was diagnosed previously with thalassemia and developed worsening in her hematological cell lines, it is worthy to investigate for possible other coexisting causes. Peripheral smear finding and autoimmune antibody can give us clue about the underlying cause and the need for further testing.

Conclusions
The association between beta-thalassemia in general and SLE is rare, and it is rarer in HbE/beta-thalassemia and SLE based on the reported case all over the world. More severe symptoms can present in concomitant disease. This warrants early suspicion and diagnosis of other diseases that might worsen the primary disease.

Additional Information

Disclosures

Human subjects: All authors have confirmed that this study did not involve human participants or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors declare that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Justiz Vaillant AA, Goyal A, Bansal P, Varacallo M: Systemic Lupus Erythematosus (SLE). StatPearls Publishing, Treasure Island, FL; 2020.
2. Castellino G, Govoni M, Padovan M, Rizzo N, Trotta F: Beta thalassaemic trait and systemic lupus erythematosus. Ann Rheum Dis. 2005, 64:653-654. 10.1136/ard.2004.023689
3. De Sanctis V, Kattamis C, Canatan D, et al.: β-thalassemia distribution in the old world: an ancient disease seen from a historical standpoint. Mediterr J Hematol Infect Dis. 2017, 9:e2017018.
4. Kanbour I, Chandra P, Soliman A, et al.: Severe liver iron concentrations (LIC) in 24 patients with β-thalassemia major: correlations with serum ferritin, liver enzymes and endocrine complications. Mediterr J Hematol Infect Dis. 2018, 10:e2018062. 10.4084/MJHID.2018.062
5. Soliman AT, Yasin M, El-Awwa A, De Sanctis V: Detection of glycemic abnormalities in adolescents with beta thalassemia using continuous glucose monitoring and oral glucose tolerance in adolescents and young adults with β-thalassemia major: pilot study. Indian J Endocrinol Metab. 2015, 17:490-495. 10.4103/2230-8210.111647
6. De Sanctis V, Elseedy H, Soliman AT, et al.: Acquired hypogonadotropic hypogonadism (AHH) in thalassemia major patients: an underdiagnosed condition?. Mediterr J Hematol Infect Dis. 2016, 8:e2016001. 10.4084/MJHID.2016.001
7. Soliman A, Yassin M, Al Yafei F, Al-Naimi L, Almarri N, Sabt A, De Sanctis V: Longitudinal study on liver functions in patients with thalassemia major before and after deferasirox (DFX)
therapy. Medit J Hematol Infect Dis. 2014, 6:e2014025. 10.4084/MJHID.2014.025
8. Yassin MA, Soliman AT, De Sanctis V, Abdelrahman MO, Bedair EM, AbdelGawad M: Effects of the anti-receptor activator of nuclear factor kappa B ligand denusomab on beta thalassemia major-induced osteoporosis. Indian J Endocrinol Metab. 2014, 18:546-551. 10.4103/2230-8210.137516
9. Altinoz MA, Gedikoglu G, Deniz G: β-Thalassaemia trait association with autoimmune diseases: β-globin locus proximity to the immunity genes or role of haemorphins?. Immunopharmacol Immunotoxicol. 2012, 34:181-190. 10.3109/08923973.2011.599391
10. Newman K, Owlia MB, El-Hemaidi I, Akhtari M: Management of immune cytopenias in patients with systemic lupus erythematosus: old and new. Autoimmun Rev. 2013, 12:784-791. 10.1016/j.autrev.2013.02.001
11. Fucharoen S, Weatherall DJ: The hemoglobin E thalassemias. Cold Spring Harb Perspect Med. 2012, 2:a011734. 10.1101/cshperspect.a011734
12. Kaloterakis A, Filiotou A, Haziyannis S, Vaiopoulos G, Lutradi-Anagnostou A: Sickle cell/β0-thalassemia and systemic lupus erythematosus. Lupus. 1999, 8:778-779. 10.1191/096120399678840972
13. Paul R, Seal K, Das S, Chakravarti HN, Bhattacharya R: E beta thalassemia complicated by steroid responsive auto immune hemolytic a nemia due to systemic lupus erythematosus. Int Res J Pharm. 2013, 4:241-242. 10.7897/2230-8407.04450